Skip to main content
. Author manuscript; available in PMC: 2014 May 22.
Published in final edited form as: J Immunol. 2011 May 20;187(1):450–461. doi: 10.4049/jimmunol.1000964

FIGURE 4.

FIGURE 4

FIZZ2 induction of type I collagen and α-SMA in MLFs. A, Normal MLFs were treated with the indicated doses of FIZZ2 for the indicated times and then analyzed for type I procollagen mRNA levels by qPCR. B, MLFs were treated with FIZZ2 (10 ng/ml) or TGF-β1 (0.1 ng/ ml), or both as indicated, and then analyzed for type I procollagen mRNA by qPCR. For qPCR analysis, the GAPDH signal was used as internal control (reference) and the respective untreated controls (or “None”) as calibrator for the 2−ΔΔCT calculations (equivalent to fold change over controls). Results are shown as mean ± SE (n = 3). *p < 0.05 (compared with control in A and B, respectively). C, MLFs were treated with the indicated doses of FIZZ2 and then analyzed for α-SMA protein levels by Western blotting. A representative Western blot is shown from three independent experiments with similar results.